RBM15

Across TCGA pan-cancer cohorts, RBM15 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBM15 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RBM15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBM15 expression acts as an unfavorable survival marker.

KIRC, SKCM, and LUSC are the cancer types where RBM15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.062	0.789	<.001	24	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →
LUSC	DFS	Median	II,III,IV	0.127	0.674	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RBM15–KIRC (OS)

Open the KIRC breakdown →